Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.980
-0.020 (-1.01%)
At close: Jun 27, 2025, 4:00 PM
1.840
-0.140 (-7.07%)
After-hours: Jun 27, 2025, 6:46 PM EDT
Entera Bio Employees
As of December 31, 2024, Entera Bio had 20 total employees, including 18 full-time and 2 part-time employees. The number of employees increased by 2 or 11.11% compared to the previous year.
Employees
20
Change (1Y)
2
Growth (1Y)
11.11%
Revenue / Employee
$11,150
Profits / Employee
-$504,550
Market Cap
89.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ENTX News
- 7 weeks ago - Entera Bio Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders - GlobeNewsWire
- 4 months ago - Entera Bio to Participate in Upcoming Events - GlobeNewsWire
- 5 months ago - Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 8 months ago - Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 9 months ago - Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders - GlobeNewsWire
- 11 months ago - Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewsWire